Pfizer Discontinues Seagen-Developed Solid Tumor ADC Program SGN-MesoC2, Highlighting Persistent ADC Development Challenges

July 19, 2026

BioSpace USA

Overview

Pfizer has discontinued another Seagen-developed antibody-drug conjugate (ADC) program for solid tumors, SGN-MesoC2, just weeks after another Seagen-acquired ADC failed a Phase 3 lung cancer study. This cessation underscores the inherent challenges in ADC development, even for targeted therapies originating from specialized companies. The decision highlights the high attrition rates and complexities involved in bringing ADCs to market.

In Depth

Key Findings

Pfizer has made the decision to discontinue the development program for SGN-MesoC2, an antibody-drug conjugate (ADC) candidate developed by Seagen for solid tumors. This move comes just weeks after another Seagen-acquired ADC failed a Phase 3 lung cancer study. The consecutive program halts underscore the persistent and inherent challenges in ADC development, even for targeted therapies originating from specialized companies in the bioconjugate space.

Technical / Clinical Details

SGN-MesoC2 was designed as an ADC targeting mesothelin, an antigen often overexpressed in various hard-to-treat solid tumors such as malignant mesothelioma and pancreatic cancer. While the specific reasons for discontinuation were not fully detailed, common factors contributing to ADC development failures include safety issues (e.g., systemic toxicity), lack of anticipated efficacy, or pharmacokinetic challenges (e.g., insufficient tumor delivery). Pfizer’s decision on SGN-MesoC2 highlights the difficulty in translating promising preclinical or early-clinical results into definitive efficacy and safety profiles in later-stage clinical trials. The complexity lies in optimizing the antibody’s specificity, the payload’s potency, the linker’s stability, and the overall drug-to-antibody ratio to achieve a favorable therapeutic index.

Background & Context

Pfizer recently acquired Seagen in a multi-billion dollar deal to bolster its oncology pipeline, specifically leveraging Seagen’s expertise as a leader in ADC development. Seagen had a track record of bringing multiple approved ADCs to market with potent payloads, stable linkers, and efficient conjugation technologies. Therefore, Seagen’s pipeline assets were expected to be a significant pillar of Pfizer’s oncology portfolio. However, the discontinuation of SGN-MesoC2 and the prior Phase 3 failure for another ADC serve as a stark reminder of the intrinsic complexities and risks associated with the ADC modality. The success of an ADC hinges on numerous interdependent factors, including target selection, payload choice, linker optimization, and identification of appropriate patient populations.

Strategic Significance & Outlook

The discontinuation of SGN-MesoC2 will likely prompt a re-evaluation within Pfizer’s broader ADC pipeline, but it is unlikely to diminish the fundamental view that ADCs are a vital modality in cancer treatment. Instead, these experiences will likely accelerate the pursuit of more stringent early-stage screening, more precise biomarker-driven patient selection, and continued innovation in linker-payload technologies. ADC development remains a ‘high-risk, high-reward’ field, offering tremendous therapeutic potential but also high attrition rates. The industry as a whole is expected to learn from these instances, moving towards even more refined ADC design and development strategies. Investors will be observing not just the success or failure of individual pipeline assets, but also how companies manage risk and drive continuous innovation in this dynamic sector.

Source: https://www.biospace.com/drug-development/pfizer-scraps-seagen-developed-adc-for-solid-tumors

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.